Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet ...

--Scopus BioPharma Inc. and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti ...

Scopus BioPharma Inc. is a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need. Scopus currently conducts substantially all of ...

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer ...

Short interest in Scopus BioPharma Corp (OOTC:SCPS) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short.

Check out our SCPS stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

On Thursday, shares of Scopus Biopharma I (NASDAQ: SCPS) experienced volatile short activity. After the activity, the stock price went up +44.85% to $0.3401. The overall sentiment for SCPS has ...

News provided by Scopus BioPharma Inc. Nov 07, 2023, 9:15 AM ET DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests ...

Review Scopus BioPharma Inc (SCPS:PINX) stock and the current sustainability and ESG risk rating to help with your investing decisions.

News provided by Scopus BioPharma Inc. Nov 07, 2023, 9:15 AM ET DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests ...